A real-world data analysis of the use of hepatoprotective drugs in outpatients in six cities of China from 2015 to 2019
10.3969/j.issn.1001-5256.2021.11.021
- VernacularTitle:2015年—2019年中国6城市门诊肝病辅助用药的真实世界数据分析
- Author:
Zinan ZHAO
1
,
2
,
3
;
Junling LYU
1
,
2
,
3
;
Lei YANG
4
,
5
,
6
;
Yatong ZHANG
1
,
2
,
3
Author Information
1. Department of Pharmacy, National Center of Gerontology, Beijing Hospital
2. Institute of Geriatric Medicine, Chinese Academy of Medical Sciences
3. Assessment of Clinical Drugs Risk and Individual Application Key Laboratory, Beijing 100730, China
4. Clinical Trial Center, Beijing Hospital
5. National Center of Gerontology
6. Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing 100730, China
- Publication Type:Original articles_Other liver diseases
- Keywords:
Hepatoprotective Drugs;
Drug Prescriptions;
Real-World Data
- From:
Journal of Clinical Hepatology
2021;37(11):2595-2599
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the use of hepatoprotective drugs in China in recent years, and to put forward related suggestions. Methods The outpatient prescription data of hepatoprotective drugs were collected from 85 hospitals in 6 cities of China from 2015 to 2019, and a real-world data analysis was performed to analyze the payment method, issuing department, drug category, and use of hepatoprotective drugs. Results A total of 1 113 575 prescriptions were extracted, involving 38 hepatoprotective drugs such as compound glycyrrhizin, polyene phosphatidylcholine, and bicyclol. Hepatoprotective drugs were mainly in tertiary hospitals, and the highest number of prescriptions containing hepatoprotective drugs were observed in department of infectious diseases, department of gastroenterology, and department of tuberculosis. Anti-inflammatory hepatoprotective drugs accounted for the highest proportion of all prescriptions, mainly compound glycyrrhizin, polyene phosphatidylcholine, and bicyclol. Of all prescriptions, 253 429 (22.76%) had the combination of multiple hepatoprotective drugs, with the highest number of 6 drugs, among which polyene phosphatidylcholine combined with bicyclol accounted for the highest proportion. Conclusion There are large quantities of hepatoprotective drugs used by outpatients in China. At present, the hepatoprotective drugs are clinically applied rationally, but there are still some problems to be solved, such as the combination of drugs.
